• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for RIFADIN issued to SANOFI AVENTIS US

    10/11/24 11:21:40 AM ET
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNY alert in real time by email
    New Drug Application (NDA): 050627
    Company: SANOFI AVENTIS US
    • Email

    Products on NDA 050627

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    RIFADIN RIFAMPIN 600MG/VIAL INJECTABLE;INJECTION Prescription AP Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 050627

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    05/25/1989 ORIG-1 Approval Type 3 - New Dosage Form STANDARD; Orphan

    Label is not available on this site.

    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    10/10/2024 SUPPL-37 Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050420s092,050627s037lbl.pdf
    12/08/2023 SUPPL-36 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s091,050627s036lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/050420Orig1s091; 050627Orig1s036ltr.pdf
    08/16/2023 SUPPL-35 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s090,050627s035lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/050420Orig1s090;050627Orig1s035ltr.pdf
    02/17/2023 SUPPL-34 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s089,050627s034lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/050420Orig1s089;050627Orig1s034ltr.pdf
    02/10/2023 SUPPL-33 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s088,050627s033lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/050420Orig1s088;050627Orig1s033ltr.pdf
    01/29/2022 SUPPL-30 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050420s087,050627s030lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/050420Orig1s087; 050627Orig1s030ltr.pdf
    10/21/2021 SUPPL-29 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050420s086,050627s029lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/050420Orig1s086,050627Orig1s029ltr.pdf
    06/17/2021 SUPPL-28 Labeling-Patient Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050420s085,050627s028lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/050420Orig1s085; 050627Orig1s028ltr.pdf
    05/12/2020 SUPPL-27 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050420s084,050627s027lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/050420Orig1s084,050627Orig1s027ltr.pdf
    08/27/2019 SUPPL-25 Labeling-Package Insert Label (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050420s083,050627s025lbl.pdf
    02/28/2019 SUPPL-23 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050420s080,050627s023lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/050420Orig1s080, 050627Orig1s023ltr.pdf
    01/23/2019 SUPPL-21 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050420s078,050627s021lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/050420Orig1s078, 050627Orig1s021ltr.pdf
    01/08/2018 SUPPL-20 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050420s077,050627s020lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/050420Orig1s077, 050627Orig1s020ltr.pdf
    04/24/2017 SUPPL-17 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050420s076,050627s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/050627Orig1S017,050420Orig1S076ltr.pdf
    12/02/2015 SUPPL-16 Manufacturing (CMC)

    Label is not available on this site.

    04/09/2015 SUPPL-15 Manufacturing (CMC)

    Label is not available on this site.

    02/27/2013 SUPPL-14 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050420s075,050627s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/050420Orig1s075,050627Orig1s014ltr.pdf
    11/10/2010 SUPPL-12 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/050420s073,050627s012ltr.pdf
    08/20/2004 SUPPL-8 Labeling Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50420s072,50627s008lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/50420s072,50627s008ltr.pdf
    04/12/2000 SUPPL-7 Labeling

    Label is not available on this site.

    04/12/2000 SUPPL-6 Labeling

    Label is not available on this site.

    07/28/1995 SUPPL-5 Manufacturing (CMC)-Control

    Label is not available on this site.

    09/17/1996 SUPPL-4 Labeling

    Label is not available on this site.

    03/10/1992 SUPPL-2 Labeling

    Label is not available on this site.

    06/18/1993 SUPPL-1 Labeling

    Label is not available on this site.

    Labels for NDA 050627

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    10/10/2024 SUPPL-37 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050420s092,050627s037lbl.pdf
    12/08/2023 SUPPL-36 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s091,050627s036lbl.pdf
    08/16/2023 SUPPL-35 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s090,050627s035lbl.pdf
    02/17/2023 SUPPL-34 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s089,050627s034lbl.pdf
    02/10/2023 SUPPL-33 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050420s088,050627s033lbl.pdf
    01/29/2022 SUPPL-30 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050420s087,050627s030lbl.pdf
    10/21/2021 SUPPL-29 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050420s086,050627s029lbl.pdf
    06/17/2021 SUPPL-28 Labeling-Patient Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050420s085,050627s028lbl.pdf
    05/12/2020 SUPPL-27 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/050420s084,050627s027lbl.pdf
    08/27/2019 SUPPL-25 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050420s083,050627s025lbl.pdf
    02/28/2019 SUPPL-23 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050420s080,050627s023lbl.pdf
    01/23/2019 SUPPL-21 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/050420s078,050627s021lbl.pdf
    01/08/2018 SUPPL-20 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050420s077,050627s020lbl.pdf
    04/24/2017 SUPPL-17 Labeling-Package Insert Label (PDF) Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050420s076,050627s017lbl.pdf
    02/27/2013 SUPPL-14 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050420s075,050627s014lbl.pdf
    11/10/2010 SUPPL-12 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050420s073,050627s012lbl.pdf
    08/20/2004 SUPPL-8 Labeling Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/50420s072,50627s008lbl.pdf

    Therapeutic Equivalents for NDA 050627

    RIFADIN

    INJECTABLE;INJECTION; 600MG/VIAL
    TE Code = AP

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
    RIFADIN RIFAMPIN 600MG/VIAL INJECTABLE;INJECTION Prescription Yes AP 050627 SANOFI AVENTIS US
    RIFAMPIN RIFAMPIN 600MG/VIAL INJECTABLE;INJECTION Prescription No AP 065502 EPIC PHARMA LLC
    RIFAMPIN RIFAMPIN 600MG/VIAL INJECTABLE;INJECTION Prescription No AP 091181 FRESENIUS KABI USA
    RIFAMPIN RIFAMPIN 600MG/VIAL INJECTABLE;INJECTION Prescription No AP 064217 HIKMA
    RIFAMPIN RIFAMPIN 600MG/VIAL INJECTABLE;INJECTION Prescription No AP 205039 HIKMA PHARMS
    RIFAMPIN RIFAMPIN 600MG/VIAL INJECTABLE;INJECTION Prescription No AP 065421 MYLAN LABS LTD
    Get the next $SNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNY

    DatePrice TargetRatingAnalyst
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    3/21/2025$65.00Neutral
    Goldman
    1/30/2025Sell → Hold
    Deutsche Bank
    7/26/2024$55.00 → $60.00Buy
    Argus
    1/23/2024$55.00Equal-Weight
    Morgan Stanley
    1/16/2024Buy
    UBS
    12/5/2023Overweight → Neutral
    JP Morgan
    10/30/2023Buy → Hold
    Stifel
    More analyst ratings

    $SNY
    Financials

    Live finance-specific insights

    See more
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

      ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, toda

      5/13/24 7:00:00 AM ET
      $FULC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

      ― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today to discuss the collaboration and other recent corporate developments, in conjunction with the first quarter 2024 financial results ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a c

      5/13/24 6:00:00 AM ET
      $FULC
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi Bridging the Gap between the Homeless and Society via Futsal

      Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game

      10/17/23 9:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

      BRIDGEWATER, N.J., Aug. 3, 2022 /PRNewswire/ -- Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses. Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President of Sanofi France, will lead the business unit responsible for serving the Diabetes, Cardiovascular and Transplant communities effective September 1. Bogillot joined Sanofi in 2015, and has held various positions within the company, including as Executive Director of Global Policy based in the U.S. and Chief of Staff to the CEO. In March 2020, he was appointed President of Sanofi France, where he has led

      8/3/22 2:53:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sanofi

      SC 13G/A - Sanofi (0001121404) (Subject)

      11/7/24 2:49:36 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sanofi

      SC 13G - Sanofi (0001121404) (Filed by)

      5/31/24 4:30:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sanofi (Amendment)

      SC 13G/A - Sanofi (0001121404) (Subject)

      2/14/24 3:57:49 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence

      MORRISTOWN, N.J., May 22, 2025 /PRNewswire/ -- Sanofi today announces the formal opening of the company's new flagship US offices, unveiling a state-of-the-art modern workplace fostering collaboration and innovation with the ultimate goal of bringing medicines and vaccines to patients faster. New Jersey Governor Phil Murphy and Morristown officials were expected to attend the ribbon-cutting ceremony along with Sanofi CEO Paul Hudson and other senior company officials. The Morristown offices are the latest step in the delivery of Sanofi's science-driven, best-in-class workplace portfolio worldwide, notably an expansive corporate hub and R&D center in Cambridge, Massachusetts, which opened in

      5/22/25 5:30:00 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

      - Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 - - Acquisition expected to strengthen development path for the oral small molecule TREM2 agonist program, including VG-3927, a Phase 2-ready clinical candidate for potential treatment of Alzheimer's disease – - Companies expect transaction to close in third quarter of 2025 - WATERTOWN, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (NASDAQ:VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for

      5/21/25 7:30:46 PM ET
      $SNY
      $VIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)

      Companies will collaborate on an AI-powered care improvement solution for patients with high-risk COPD Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year partnership with Sanofi (NASDAQ:SNY), an innovative global healthcare company, and Regeneron (NASDAQ:REGN), a leading biotechnology company, to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease (COPD). With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care acceleration solution that will leverage electronic health record (EHR) data and artificial intelligence (AI) to advance the detect

      5/20/25 7:30:00 AM ET
      $REGN
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    SEC Filings

    See more
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      5/30/25 10:51:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      5/22/25 8:09:03 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Sanofi

      SD - Sanofi (0001121404) (Filer)

      5/21/25 10:55:31 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

      For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

      3/28/25 10:17:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

      For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

      2/14/25 3:00:13 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

      Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

      11/4/24 4:49:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exane BNP Paribas initiated coverage on Sanofi with a new price target

      Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00

      4/15/25 12:40:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Sanofi with a new price target

      Goldman initiated coverage of Sanofi with a rating of Neutral and set a new price target of $65.00

      3/21/25 8:12:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sanofi upgraded by Deutsche Bank

      Deutsche Bank upgraded Sanofi from Sell to Hold

      1/30/25 3:33:45 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

      4 - Sanofi (0001121404) (Reporting)

      8/2/21 8:34:24 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by Sanofi

      3 - Sanofi (0001121404) (Reporting)

      7/28/21 8:32:04 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care